Adicet Bio Inc. Common Stock (ACET)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Adicet is a clinical-stage biotech with 102 employees. It is developing allogeneic gamma delta T-cell therapies; prula-cel targets CD20 for autoimmune disease, and ADI-212 targets PSMA. I see no revenue in the filed figures, including fiscal Q2 2026, the quarter ended 2026-06-30. Net losses were $21.4M in that quarter, $20.2M in fiscal Q1 2026, $26.9M in fiscal Q3 2025, and $31.2M in fiscal Q2 2025. Full-year net losses were $116.8M in FY2025, $117.1M in FY2024, and $142.7M in FY2023. This is not a business with a durable moat; it is a cash-consuming research effort. Financial health is weak: FairStock reports a Piotroski F-Score of 1/9 and an Altman Z-Score of -4.34. Trailing free cash flow is -$85.0M, a -177.6% FCF yield against the $47.8M market cap at the 2026-10-13 close. Debt/equity is low at 0.11, but ROE is -78.08% and ROCE is -41.66%. The P/B of 0.46 and P/E of -0.49 are FairStock calculations tied to that close; a sub-book price is not a margin of safety when losses are this large. The 52-week range of $5.10-$17.04 shows the stock near its low. The FairStock score is 41/100, and the Lynch category is none because of losses in each of the last four years. The supplied profit growth of 31.58% cannot outweigh zero revenue and persistent losses. Until there is clinical validation and a credible path to revenue, this looks speculative, not value.

In plain English: Adicet Bio is a small clinical-stage biotech company developing cell therapies for autoimmune diseases and cancer. It has no reported revenue in the periods shown and continues to lose large amounts of money, so the business looks weak and unproven. The stock looks cheap on paper, but heavy cash losses mean that low price is not the same as safety.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer